Increasing Transparency in Generic Drug Applications Act
USA117th CongressS-4338| Senate
| Updated: 5/26/2022
Margaret Wood Hassan
Democratic Senator
New Hampshire
Cosponsors (1)
Health, Education, Labor, and Pensions Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Increasing Transparency in Generic Drug Applications Act This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health
Administrative law and regulatory proceduresDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationPrescription drugs
Increasing Transparency in Generic Drug Applications Act
USA117th CongressS-4338| Senate
| Updated: 5/26/2022
Increasing Transparency in Generic Drug Applications Act This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Margaret Wood Hassan
Democratic Senator
New Hampshire
Cosponsors (1)
Health, Education, Labor, and Pensions Committee
Health
Related Bills
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Administrative law and regulatory proceduresDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationPrescription drugs